The global sector for Behçet's disease therapeutics is experiencing a period of substantial growth, driven by an increasing prevalence of the disease and advancements in treatment options. The demand for effective therapies to manage the diverse symptoms of Behçet's disease is propelling this growth. Pharmaceutical companies are actively developi